Megan Cully
megancully.bsky.social
Megan Cully
@megancully.bsky.social
Biochemist, biotech/healthtech, building strategic partnerships and providing direction of travel. Formerly a Nat Rev Drug Disc editor, U Calgary, U Toronto and CRUK-LRI alum
Inspired by @tim-spector.bsky.social 's recent conversation with Valter Longo www.youtube.com/watch?v=TI7L... . Yes, I finally caved and am currently wearing a Zoe patch!
Longevity expert: Try this new type of fasting | Dr. Valter Longo and Prof. Tim Spector
YouTube video by ZOE
www.youtube.com
January 24, 2025 at 11:16 AM
I think most trainees would jump at the opportunity to get some IP education! Great idea, Randal Serafini, Micalla Curtis and Stella Allmperti
January 9, 2025 at 2:44 PM
Welcome! Me too. Nice to re-connect.
January 7, 2025 at 9:36 AM
You're right, it requires co-infection with 2+ AAVs, so the total number of AAV particles administered is likely higher (although I wonder if permissive cells likely take up multiple AAVs per cell, meaning that most cells that are transfected will be co-transfected). So decreasing dose is still key
January 7, 2025 at 9:34 AM
Although vaccines have historically been used to prevent infectious diseases, their future lies in noncommunicable ones. The HPV vaccine led the way in cervical cancer - next on the 'hit list' should be CMV and EBV.
January 6, 2025 at 11:58 AM
And neurodegenerative conditions, too!
January 6, 2025 at 11:54 AM
Technical advances in AAVs are coming, too. My favourite way to increase payload: StichR (www.science.org/doi/10.1126/...). Cell/tissue targeting: evolution-based methods (4DMT 4dmoleculartherapeutics.com). The remaining problem? Avoiding uptake by the liver.
Ribozyme-activated mRNA trans-ligation enables large gene delivery to treat muscular dystrophies
Ribozymes are small catalytic RNA sequences capable of nucleotide-specific self-cleavage found widespread in nature. Ribozyme cleavage generates distinct 2′,3′-phosphate and 5′-hydroxyl termini that r...
www.science.org
January 6, 2025 at 11:49 AM